Search

everythinglearnresearchcommunity

for

Search:↓

Korean scientists developed a red light therapy that reduces a hair loss marker by 92%. Users discussed the benefits and drawbacks of natural sunlight versus red light caps for hair health, with some suggesting supplements for vitamin D.

The conversation discusses creating a customized minoxidil formulation with tretinoin, azelaic acid, and caffeine, but there are concerns about foam stabilization due to acidity. The user seeks advice on the best formulation for effective results.

The user shared progress pictures after 4 months of using 5% topical minoxidil and microneedling for hair loss. They discussed their positive results and experiences with these treatments.

Oral minoxidil and finasteride are the main treatments for hair loss, with microneedling as an additional method. Tretinoin gel is not necessary with oral minoxidil but can be used for skincare.

User shares 4-month progress using daily minoxidil, topical finasteride, and microneedling. Results spark debate on effectiveness and authenticity.

Pelage Pharmaceuticals' PP405, a new hair loss treatment, was recognized by Time Magazine as one of the best inventions of 2025. The conversation expresses optimism about the recognition of this in-development treatment.

A user is treating their advanced hair loss with a regimen including topical finasteride, minoxidil, hydrocortisone, stem cell serum, peptide serum, multivitamins, he shou wu tea, derma pen, argan oil, and a derma roller. Replies suggest it's too early to judge progress and recommend staying consistent, with one suggesting oral minoxidil as an additional option.

The user shared 60-day progress using 5% topical minoxidil, 1mg finasteride, and recently started microneedling with a derma stamp. Users commented on the difficulty of seeing changes due to hair length and even thinning.

A user shared their positive experience with Roots by GA, a company that creates personalized hair loss treatments based on DNA analysis, which confirmed their inability to tolerate finasteride. The user is satisfied with their progress 30 days after a hair transplant and the customized formula they received.

Minoxidil may age skin by slowing collagen synthesis, but using collagen peptides and a basic skincare routine might counteract this. Foam minoxidil could reduce systemic absorption and avoid alcohol-related side effects.

The user is considering using CB or clascoterone for hair loss, potentially as an alternative to RU. They're also contemplating asking a dermatologist for topical clascoterone cream to apply to their temple.

A user shared their 9-month progress using RU58841 at 2% daily for hair regrowth, initially starting at 5% but reducing the dose due to early signs of gynecomastia, which has since mostly resolved. They achieved their goal of regrowing hair at the temples and hairline.

Oral minoxidil is claimed to be more effective and easier to use than topical minoxidil, with a 100% response rate, but it may cause unwanted body hair growth and has potential heart-related side effects. Topical minoxidil is less effective for many due to enzyme limitations, can cause scalp issues, and is more challenging to apply, but it avoids systemic side effects.

A user experienced severe side effects from using topical minoxidil sublingually, including muscle cramps, dizziness, and high potassium levels. They were advised to stop and seek medical help, emphasizing that topical minoxidil is not safe for ingestion due to its alcohol content.

A user shared their 88-day progress using 1.25mg finasteride, topical minoxidil, and weekly 1mm microneedling, noting improvement from NW 4.5 to around NW 3. Another user complimented the progress.

The user experienced rapid hair growth using Minoxidil, Finasteride, and microneedling, with some initial skin irritation from a retinal serum. They stopped microneedling due to limited results but may continue due to positive anecdotal evidence.

The user reports improvement in temple hair after three weeks of using finasteride, minoxidil, ketoconazole, microneedling, stemoxydine, and follicopeptide. They note visible progress by maintaining the same hair length for comparison.

Veradermics' new hair loss treatment, VDPHL01, is likely a modified release oral minoxidil, which has received $75 million in funding for clinical trials. Despite skepticism about investing in a known treatment, some believe it could offer improved efficacy and reduced side effects.

User discusses potential hair loss treatment SCUBE3 and shares mixed opinions on its effectiveness. One user reports positive results after applying SCUBE3 following microneedling.

PP405 shows promise in hair loss treatment, but stem cell therapy using adipose-derived stem cells and ATP also successfully reversed androgenetic alopecia in mice. Stem cell therapy is costly, and some doubt the effectiveness of PP405 based on press releases.

A new topical treatment, PP405, shows promising results for hair regrowth, potentially outperforming existing treatments like finasteride and minoxidil. However, it may still need to be combined with DHT blockers for optimal results, and its long-term effectiveness remains uncertain.

A 45-year-old user shared progress pictures after 4 months of using a topical gel with 2.5% finasteride and 5% minoxidil once daily. The second picture shows significant improvement in hair growth.

Verteporfin is discussed as a potential treatment for hair regrowth, but skepticism exists about its effectiveness in regenerating extracted hair follicles. The conversation also mentions the possibility of needing a hair transplant by 2028.

The user shared their experience with CB-03-01 (Breezula/Clascoterone) for hair loss, noting reduced shedding and improved hair appearance but experiencing significant sleep disturbances and low energy due to HPA axis suppression. They decided to stop using it due to these side effects and are waiting for GT20029 as an alternative.

A user experienced significant hair density increase after 80 days using oral finasteride, topical minoxidil, and microneedling with a derma pen. They reported minimal side effects and attributed their success to being a hyper responder to the treatments.

FCE 28260 (PNU 156765), an under-explored 5α-reductase inhibitor, showcases promising results in research by Giudici et al., outperforming well-known treatments like Finasteride in reducing the conversion of testosterone to DHT. Its superior efficacy, demonstrated through lower IC50 values in both natural and human recombinant enzyme studies, suggests it could offer more effective management of DHT-related conditions. Additionally, its lower molecular weight hints at better potential for topical application, potentially offering advantages in treating conditions such as androgenic alopecia. Despite its potential, it has not advanced in development, possibly due to financial limitations, leaving its therapeutic prospects and side effect profile largely unexplored.

KY19382 is discussed as a potential treatment for creating new hair follicles and possibly curing hair loss. The conversation seeks user experiences and sourcing information for KY19382.

A discount code for 20% off at Anageninc is shared, valid for purchasing RU58841 or Pyri from May 10-11, 2025. The conversation focuses on hair loss treatments using RU58841.

Veradermics has a market cap over a billion dollars, comparable to Cosmo pharmaceutical. Users discuss using Kintor's Pirylutamide for hair loss.

A new stem cell method for culturing hair follicles is being developed as an alternative to Minoxidil, finasteride, and RU58841. There are concerns about its cost and accessibility despite plans for commercialization.